Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
2000 1
2001 1
2002 1
2005 4
2006 4
2007 3
2008 2
2009 5
2010 2
2011 4
2012 5
2013 2
2016 3
2018 1
2020 4
2021 3
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Modi S, et al. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35665782 Free PMC article. Clinical Trial.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suárez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J; DANUBE study investigators. Powles T, et al. Among authors: tsiatas m. Lancet Oncol. 2020 Dec;21(12):1574-1588. doi: 10.1016/S1470-2045(20)30541-6. Epub 2020 Sep 21. Lancet Oncol. 2020. PMID: 32971005 Clinical Trial.
Investigation of Clinically Significant Molecular Aberrations in Patients with Prostate Cancer: Implications for Personalized Treatment, Prognosis and Genetic Testing.
Fountzilas E, Kouspou M, Eliades A, Papadopoulou K, Bournakis E, Goussia A, Tsiatas M, Achilleos A, Tsangaras K, Billioud G, Loizides C, Lemesios C, Kypri E, Ioannides M, Koumbaris G, Levva S, Vakalopoulos I, Paliouras A, Pervana S, Koinis F, Bumci R, Christopoulou A, Meditskou S, Psyrri A, Boukovinas I, Visvikis A, Karavasilis V, Koukoulis GK, Kotsakis A, Giannakis D, Fountzilas G, Patsalis PC. Fountzilas E, et al. Among authors: tsiatas m. Int J Mol Sci. 2023 Jul 23;24(14):11834. doi: 10.3390/ijms241411834. Int J Mol Sci. 2023. PMID: 37511593 Free PMC article.
Future perspectives in cancer immunotherapy.
Tsiatas M, Mountzios G, Curigliano G. Tsiatas M, et al. Ann Transl Med. 2016 Jul;4(14):273. doi: 10.21037/atm.2016.07.14. Ann Transl Med. 2016. PMID: 27563660 Free PMC article.
Investigation of prognostic biomarkers in patients with urothelial carcinoma treated with platinum-based regimens.
Papadopoulou K, Koliou GA, Tsimiliotis D, Kotoula V, Foukas P, Goussia A, Tsiatas M, Visvikis A, Chatzopoulos K, Nifora M, Charchanti A, Koumarianou A, Christodoulou C, Pectasides D, Psyrri A, Fostira F, Fountzilas G, Samantas E. Papadopoulou K, et al. Among authors: tsiatas m. Urol Oncol. 2022 Dec;40(12):538.e15-538.e24. doi: 10.1016/j.urolonc.2022.07.007. Epub 2022 Aug 28. Urol Oncol. 2022. PMID: 36041976
43 results